BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ichikawa W, Takahashi T, Suto K, Shirota Y, Nihei Z, Shimizu M, Sasaki Y, Hirayama R. Simple combinations of 5-FU pathway genes predict the outcome of metastatic gastric cancer patients treated by S-1. Int J Cancer. 2006;119:1927-1933. [PMID: 16736497 DOI: 10.1002/ijc.22080] [Cited by in Crossref: 42] [Cited by in F6Publishing: 39] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Showalter SL, Showalter TN, Witkiewicz A, Havens R, Kennedy EP, Hucl T, Kern SE, Yeo CJ, Brody JR. Evaluating the drug-target relationship between thymidylate synthase expression and tumor response to 5-fluorouracil. Is it time to move forward? Cancer Biol Ther. 2008;7:986-994. [PMID: 18443433 DOI: 10.4161/cbt.7.7.6181] [Cited by in Crossref: 38] [Cited by in F6Publishing: 44] [Article Influence: 2.9] [Reference Citation Analysis]
2 Ichikawa W, Sasaki Y. Challenges in predicting the clinical outcome in S-1-based chemotherapy for gastric cancer patients. Int J Clin Oncol 2008;13:206-11. [DOI: 10.1007/s10147-008-0786-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
3 Yamada Y, Boku N, Nishina T, Yamaguchi K, Denda T, Tsuji A, Hamamoto Y, Konishi K, Tsuji Y, Amagai K. Impact of excision repair cross-complementing gene 1 (ERCC1) on the outcomes of patients with advanced gastric cancer: correlative study in Japan Clinical Oncology Group Trial JCOG9912. Ann Oncol. 2013;24:2560-2565. [PMID: 23884439 DOI: 10.1093/annonc/mdt238] [Cited by in Crossref: 29] [Cited by in F6Publishing: 21] [Article Influence: 3.6] [Reference Citation Analysis]
4 Griffith M, Mwenifumbo JC, Cheung PY, Paul JE, Pugh TJ, Tang MJ, Chittaranjan S, Morin RD, Asano JK, Ally AA. Novel mRNA isoforms and mutations of uridine monophosphate synthetase and 5-fluorouracil resistance in colorectal cancer. Pharmacogenomics J. 2013;13:148-158. [PMID: 22249354 DOI: 10.1038/tpj.2011.65] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
5 Kusakari C, Soda H, Nakamura Y, Yamaguchi H, Kitazaki T, Nakano H, Matsubara Y, Hayashi T, Nagasaki T, Nagayasu T, Kohno S. Mediastinal signet-ring cell carcinoma of unknown primary: long-term survival by treatment with S-1, a novel derivative of 5-fluorouracil. Lung Cancer 2007;56:139-41. [PMID: 17208329 DOI: 10.1016/j.lungcan.2006.11.020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
6 Zhang C, Liu H, Ma B, Song Y, Gao P, Xu Y, Yu D, Wang Z. The Impact of the Expression Level of Intratumoral Dihydropyrimidine Dehydrogenase on Chemotherapy Sensitivity and Survival of Patients in Gastric Cancer: A Meta-Analysis. Dis Markers 2017;2017:9202676. [PMID: 28255193 DOI: 10.1155/2017/9202676] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
7 Miyazaki I, Kawai T, Harada Y, Moriyasu F. A predictive factor for the response to S-1 plus cisplatin in gastric cancer. World J Gastroenterol 2010;16:4575-82. [PMID: 20857529 DOI: 10.3748/wjg.v16.i36.4575] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
8 Hiraki M, Sato S, Kai K, Ohtsuka T, Kohya N, Kitajima Y, Nakafusa Y, Tokunaga O, Miyazaki K. A long-time survivor of alpha-fetoprotein-producing gastric cancer successfully treated by fluoropyrimidine-based chemotherapy: a case study. Clin J Gastroenterol 2009;2:331-7. [PMID: 26192608 DOI: 10.1007/s12328-009-0105-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
9 Wang D, Yu X, Wang X. High/positive expression of 5-fluorouracil metabolic enzymes predicts better response to S-1 in patients with gastric cancer: a meta-analysis. Int J Biol Markers. 2016;31:e101-e109. [PMID: 27012156 DOI: 10.5301/jbm.5000202] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
10 Wang Q, Liu X, Chen C, Chen J, Xu B, Chen L, Zhou J, Huang Y, Chen W, Teng R, Zhao W, Jin L, Shen J, Shen J, Yen Y, Wang L. A predictive signature for oxaliplatin and 5-fluorouracil based chemotherapy in locally advanced gastric cancer. Transl Oncol 2021;14:100901. [PMID: 33091827 DOI: 10.1016/j.tranon.2020.100901] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Ishido K, Azuma M, Koizumi W, Takeuchi A, Sakuramoto S, Watanabe M, Okayasu I. Evaluation of prognostic factors for the response to S-1 in patients with stage II or III advanced gastric cancer who underwent gastrectomy. Pharmacogenet Genomics. 2009;19:955-964. [PMID: 19898266 DOI: 10.1097/fpc.0b013e328333351b] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
12 Park SR, Kong SY, Nam BH, Choi IJ, Kim CG, Lee JY, Cho SJ, Kim YW, Ryu KW, Lee JH. CYP2A6 and ERCC1 polymorphisms correlate with efficacy of S-1 plus cisplatin in metastatic gastric cancer patients. Br J Cancer. 2011;104:1126-1134. [PMID: 21364592 DOI: 10.1038/bjc.2011.24] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 3.8] [Reference Citation Analysis]
13 Hahnvajanawong C, Chaiyagool J, Seubwai W, Bhudhisawasdi V, Namwat N, Khuntikeo N, Sripa B, Pugkhem A, Tassaneeyakul W. Orotate phosphoribosyl transferase mRNA expression and the response of cholangiocarcinoma to 5-fluorouracil. World J Gastroenterol 2012;18:3955-61. [PMID: 22912546 DOI: 10.3748/wjg.v18.i30.3955] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
14 Nishiyama M, Eguchi H. Pharmacokinetics and pharmacogenomics in gastric cancer chemotherapy. Adv Drug Deliv Rev. 2009;61:402-407. [PMID: 19133303 DOI: 10.1016/j.addr.2008.09.004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 1.7] [Reference Citation Analysis]
15 Nishiyama M. Chemotherapy for gastric cancer in Japan. Int J Clin Oncol 2008;13:191-2. [PMID: 18553225 DOI: 10.1007/s10147-008-0790-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
16 Shen X, Zhou C, Lian L, Li L, Li W, Tao M. Relationship Between the DPD and TS mRNA Expression and the Response to S-1-Based Chemotherapy and Prognosis in Patients with Advanced Gastric Cancer. Cell Biochem Biophys 2015;71:1653-61. [DOI: 10.1007/s12013-014-0387-5] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
17 He MM, Zhang DS, Wang F, Wang ZX, Yuan SQ, Wang ZQ, Luo HY, Ren C, Qiu MZ, Jin Y, Wang DS, Chen DL, Zeng ZL, Li YH, He YY, Hao YT, Guo P, Wang FH, Zeng YX, Xu RH. Phase II trial of S-1 plus leucovorin in patients with advanced gastric cancer and clinical prediction by S-1 pharmacogenetic pathway. Cancer Chemother Pharmacol 2017;79:69-79. [PMID: 27913881 DOI: 10.1007/s00280-016-3209-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
18 Naito S, Eto M, Shinohara N, Tomita Y, Fujisawa M, Namiki M, Nishikido M, Usami M, Tsukamoto T, Akaza H. Multicenter Phase II Trial of S-1 in Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma. JCO 2010;28:5022-9. [DOI: 10.1200/jco.2010.29.1203] [Cited by in Crossref: 20] [Cited by in F6Publishing: 1] [Article Influence: 1.8] [Reference Citation Analysis]
19 Yoshida K, Yamaguchi K, Osada S, Kawaguchi Y, Takahashi T, Sakashita F, Tanaka Y. Challenge for a better combination with basic evidence. Int J Clin Oncol. 2008;13:212-219. [PMID: 18553230 DOI: 10.1007/s10147-008-0793-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
20 Mohammed Ael S, Eguchi H, Wada S, Koyama N, Shimizu M, Otani K, Ohtaki M, Tanimoto K, Hiyama K, Gaber MS, Nishiyama M. TMEM158 and FBLP1 as novel marker genes of cisplatin sensitivity in non-small cell lung cancer cells. Exp Lung Res 2012;38:463-74. [PMID: 23098063 DOI: 10.3109/01902148.2012.731625] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
21 Kim JY, Shin E, Kim JW, Lee HS, Lee DW, Kim SH, Lee JO, Kim YJ, Kim JH, Bang SM, Ahn SH, Park DJ, Lee JS, Lee JS, Kim HH, Lee KW. Impact of intratumoral expression levels of fluoropyrimidine-metabolizing enzymes on treatment outcomes of adjuvant S-1 therapy in gastric cancer. PLoS One 2015;10:e0120324. [PMID: 25793299 DOI: 10.1371/journal.pone.0120324] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
22 Ogiya A, Horii R, Osako T, Ito Y, Iwase T, Eishi Y, Akiyama F. Apocrine metaplasia of breast cancer: clinicopathological features and predicting response. Breast Cancer 2010;17:290-7. [PMID: 19789945 DOI: 10.1007/s12282-009-0178-9] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
23 Kim C, Mulder K, Spratlin J. How prognostic and predictive biomarkers are transforming our understanding and management of advanced gastric cancer. Oncologist. 2014;19:1046-1055. [PMID: 25142842 DOI: 10.1634/theoncologist.2014-0006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
24 Choi IS, Lee HS, Lee KW, Kim H, Kim KH, Kim YJ, Kim JH, Kim WH, Lee JS. Biomarker analysis in patients with advanced gastric cancer treated with S-1 plus cisplatin chemotherapy: orotate phosphoribosyltransferase expression is associated with treatment outcomes. Med Oncol. 2011;28:991-998. [PMID: 20533001 DOI: 10.1007/s12032-010-9590-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
25 Kai K, Kitajima Y, Hiraki M, Satoh S, Tanaka M, Nakafusa Y, Tokunaga O, Miyazaki K. Quantitative double-fluorescence immunohistochemistry (qDFIHC), a novel technology to assess protein expression: a pilot study analyzing 5-FU sensitive markers thymidylate synthase, dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferases in gastric cancer tissue specimens. Cancer Lett 2007;258:45-54. [PMID: 17892912 DOI: 10.1016/j.canlet.2007.08.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
26 Patel JN, Fuchs CS, Owzar K, Chen Z, McLeod HL. Gastric cancer pharmacogenetics: progress or old tripe? Pharmacogenomics 2013;14:1053-64. [PMID: 23837480 DOI: 10.2217/pgs.13.88] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
27 Sano H, Wada S, Eguchi H, Osaki A, Saeki T, Nishiyama M. Quantitative prediction of tumor response to neoadjuvant chemotherapy in breast cancer: novel marker genes and prediction model using the expression levels. Breast Cancer 2012;19:37-45. [DOI: 10.1007/s12282-011-0263-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
28 Takeda M, Okamoto I, Hirabayashi N, Kitano M, Nakagawa K. Thymidylate synthase and dihydropyrimidine dehydrogenase expression levels are associated with response to S-1 plus carboplatin in advanced non-small cell lung cancer. Lung Cancer 2011;73:103-9. [DOI: 10.1016/j.lungcan.2010.10.022] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
29 Chhetri P, Giri A, Shakya S, Shakya S, Sapkota B, Pramod KC. Current Development of Anti-Cancer Drug S-1. J Clin Diagn Res 2016;10:XE01-5. [PMID: 28050491 DOI: 10.7860/JCDR/2016/19345.8776] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
30 Nishiyama M. Chemotherapy for gastric cancer in Japan. Int J Clin Oncol. 2008;13:191-192. [PMID: 18553225 DOI: 10.1007/s10147-008-0790] [Reference Citation Analysis]
31 Wang T, Wang L, Qian X, Yu L, Ding Y, Liu B. Relationship between gene expression of 5-fluorouracil metabolic enzymes and 5-fluorouracil sensitivity in primary cancer cells isolated from malignant ascites. Cancer Invest 2011;29:130-6. [PMID: 21210725 DOI: 10.3109/07357907.2010.535060] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
32 Kuyama S, Ochi N, Bessho A, Hotta K, Ikeda G, Kishino D, Kubo T, Harada D, Fujimoto N, Nakanishi M, Umeno T, Okada T, Chikamori K, Yamagishi T, Ohashi K, Ichihara E, Takigawa N, Tanimoto M, Kiura K. A phase II trial of carboplatin plus S-1 for elderly patients with advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor: The Okayama Lung Cancer Study Group Trial 1202. Lung Cancer 2017;112:188-94. [DOI: 10.1016/j.lungcan.2017.08.010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
33 Koizumi W, Tanabe S, Azuma M, Ishido K, Nishimura K, Sasaki T, Nakatani K, Higuchi K, Nakayama N, Katada C. Impacts of fluorouracil-metabolizing enzymes on the outcomes of patients treated with S-1 alone or S-1 plus cisplatin for first-line treatment of advanced gastric cancer. Int J Cancer. 2010;126:162-170. [PMID: 19588501 DOI: 10.1002/ijc.24726] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
34 Tänzer M, Liebl M, Quante M. Molecular biomarkers in esophageal, gastric, and colorectal adenocarcinoma. Pharmacol Ther. 2013;140:133-147. [PMID: 23791941 DOI: 10.1016/j.pharmthera.2013.06.005] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
35 Abu Lila AS, Moriyoshi N, Fukushima M, Huang C, Wada H, Ishida T. Metronomic S-1 dosing and thymidylate synthase silencing have synergistic antitumor efficacy in a colorectal cancer xenograft model. Cancer Letters 2017;400:223-31. [DOI: 10.1016/j.canlet.2016.11.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
36 Kawahara A, Akagi Y, Hattori S, Mizobe T, Shirouzu K, Ono M, Yanagawa T, Kuwano M, Kage M. Higher expression of deoxyuridine triphosphatase (dUTPase) may predict the metastasis potential of colorectal cancer. J Clin Pathol 2009;62:364-9. [PMID: 19052026 DOI: 10.1136/jcp.2008.060004] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
37 Yano A, Shigematsu Y, Kitano H, Hanayama A, Ozawa A, Tacho T, Fujii M. Possibility of using mRNA expression levels for nucleic acid-metabolizing enzymes within prostate cancer cells as indices for prognostic factors. Oncol Lett 2010;1:1049-53. [PMID: 22870111 DOI: 10.3892/ol.2010.165] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
38 Taomoto J, Yoshida K, Wada Y, Tanabe K, Konishi K, Tahara H, Fukushima M. Overexpression of the Orotate Phosphoribosyl-Transferase Gene Enhances the Effect of 5-Fluorouracil on Gastric Cancer Cell Lines. Oncology 2007;70:458-64. [DOI: 10.1159/000098873] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
39 Yeoh KG. How do we improve outcomes for gastric cancer? J Gastroenterol Hepatol. 2007;22:970-972. [PMID: 17524038 DOI: 10.1111/j.1440-1746.2007.04956.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 42] [Article Influence: 3.5] [Reference Citation Analysis]